Lupin has got the US health regulator’s approval for marketing a generic version of Novartis’ inhalation product Tobi that is used in treating cystic fibrosis in the American market.
The company has said in a statement that it has received the final approval from the US Food and Drug Administration (USFDA) for its Tobramycin Inhalation Solution.
The drug has been indicated for management of cystic fibrosis patients.
